Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for TreatmentAna C. Garrido-Castro, Kornélia Polyák, Nancy U. Lin|Cancer Discovery|2019Cited by 1.4k
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancerAna C. Garrido-Castro, Jordi Rodón|Breast Cancer Research|2020Cited by 145
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasisSusana García‐Recio, Lisa A. Carey, Toshinori Hinoue et al.|Nature Cancer|2022Cited by 114
Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: results from the NeoSTAR trialLaura M. Spring, Aditya Bardia, Louise Ryan et al.|Annals of Oncology|2023Cited by 77
AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involutionAmy E. Schade, Karen Cichowski, Naiara Perurena et al.|Nature|2024Cited by 56